EZH2 activates Wnt/b-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate

Objective: To investigate the link between EZH2 and Wnt/6-catenin signaling and its role in uterine fi broids (UFs) pathogenesis and explore the potential effect of natural compound methyl jasmonate (MJ) against UFs. Design: EZH2 overexpression or inhibition was achieved in human uterine leiomyoma (HuLM) cells using EZH2-expressing adenovirus or chemical EZH2 inhibitor (DZNep), respectively. The HuLM and normal uterine smooth muscle cells were treated with 0.1-3 mM of MJ, and several experiments were employed. Setting: Laboratory study. Patients(s): None. Intervention(s): Methyl jasmonate. Main Outcome Measure(s): Protein expression of EZH2, 6-catenin, and proliferating cell nuclear antigen (PCNA) was measured by Western blot as well as gene expression alterations of Wnt ligands ( Wnt5A , Wnt5b, and Wnt9A), WISP1, CTNNB1, and its responsive gene PITX2 using quantitative real-time polymerase chain reaction. The protein and ribonucleic acid (RNA) levels of several markers were measured in MJ-treated or untreated HuLM cells, including EZH2 and 6-catenin, extracellular matrix markers collagen type 1 (COL1A1) and fi bronectin (FN), proliferation markers cyclin D1 (CCND1) and PCNA, tumor suppressor marker p21, and apoptotic markers (BAX, cytochrome c, and cleaved caspase 3). Result(s): EZH2 overexpression significantly increased the gene expression of several Wnt ligands ( PITX2 , WISP1, WNT5A, WNT5B, and WNT9A), which increased nuclear translocation of 6-catenin and PCNA and eventually HuLM cell proliferation. EZH2 inhibition blocked Wnt/6-catenin signaling activation where the aforementioned genes significantly decreased as well as PCNA, cyclin D1, and PITX2 protein expression compared with those in untreated HuLM. Methyl jasmonate showed a potent antiproliferative effect on HuLM cells in a dose- and time-dependent manner. Interestingly, the dose range (0.1-0.5 mM) showed a selective growth inhibitory effect on HuLM cells, not on normal uterine smooth muscle cells. Methyl jasmonate treatment at 0.5 mM for 24 hours significantly decreased both protein and RNA levels of EZH2, 6-catenin, COL1A1, FN, CCND1, PCNA, WISP1, and PITX2 but increased the protein levels of p21, BAX, cytochrome, c and cleaved caspase 3 compared with untreated HuLM. Methyl jasmonate-treated cells exhibited down- regulation in the RNA expression of 36 genes, including CTNNB1, CCND1, Wnt5A, Wnt5B, and Wnt9A, and up-regulation in the expression of 34 genes, including Wnt antagonist genes WIF1, PRICKlE1, and DKK1 compared with control, confirming the quantitative real-time polymerase chain reaction results. Conclusion(s): Our studies provide a novel link between EZH2 and the Wnt/6-catenin signaling pathway in UFs. Targeting EZH2 with MJ interferes with the activation of wnt/6-catenin signaling in our model. Methyl jasmonate may offer a promising therapeutic option as a nonhormonal and cost-effective treatment against UFs with favorable clinical utility, pending proven safe and efficient in human clinical trials. (Fertil Steril Sci (R) 2023;4:239-56. (c) 2023 by American Society for Reproductive Medicine.)